The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro

Bone

Volumn 30, Issue 2, 2002, Pages 368-376

  Taranta, A ^a,e   Brama, M ^b,c   Teti, A ^b   De luca, V ^b,c   Scandurra, R ^c   Spera, G ^c   Agnusdei, D ^d   Termine, J D ^d   Migliaccio, S ^b,c  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d ELI LILLY AND COMPANY   (United States)

^e Address for Correspondence and Reprints: Dr Silvia Migliaccio   (Italy)

Author keywords

Estradiol; Osteoblasts; Osteoclasts; Osteoporosis; Raloxifene

Indexed keywords

CALCITRIOL; INTERLEUKIN 1BETA; INTERLEUKIN 6; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL CELL; ARTICLE; BONE TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CELL DIVISION; CYTOKINES; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION; MICE; MICE, INBRED STRAINS; OSTEOBLASTS; OSTEOCLASTS; RALOXIFENE; RECEPTORS, ESTROGEN;

EID: 0036171788     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(01)00685-8     Document Type: Article

References (53)

1. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group
2. Tartronates; A new generation of drugs affecting bone metabolism
3. Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein
4. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
5. 17-β-estradiol stimulates cancellous bone formation in female rats
6. Hormones and breast cancer; Evidence and implications for consideration of risks and benefits of hormone replacement therapy
7. A new method to isolate large numbers of rabbit osteoclast and osteoclast-like cells. Application to the characterization of serum response element binding proteins during osteoclast differentiation
8. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells
9. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
10. The contribution of trabecular architecture to cancellous bone quality
11. Evidence of estrogen receptor in normal human osteoblast-like cells
12. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene; Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
13. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia
14. Heterogeneity of binding sites and bioeffects of raloxifene on the human leukaemic cell line FLG 29.1
15. Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones
16. Raloxifene is a tissue selective agonist/antagonist that functions through the estrogen receptor
17. CP-336, 156 and estrogen identically inhibit osteoclastogenesis in rat bone marrow cultures through an apoptotic mechanism
18. Expression of colony-stimulating factor-1 in vivo during the formation of osteoclasts
19. The bone specific estrogen centochroman inhibit osteoclastic bone resportion in vitro
20. Biphasic effect of estrogen on neuronal constitutive nitric oxide synthase via Ca(2+)-calmodulin dependent mechanism
21. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta
22. Estrogen binding, receptor mRNA and biologic response in osteoblast-like osteosarcoma cells
23. Targeted disruption of Cbfa 1 results in a complete lack of bone formation owing to mutational arrest of osteoblasts
24. Hormonal pharmacology of estrogens and estrogenic compounds
25. Postmenopausal estrogen replacement therapy is associated with adverse breast cancer prognostic indices
26. Long-term prevention of post-menopausal osteoporosis by oestrogen; Evidence for an increased bone mass after delayed onset of oestrogen treatment
27. Protein measurement with the Folin phenol reagent
28. Osteoporosis and the risk of hip fracture
29. Estrogens modulate the responsiveness of osteoblast-like cells (ROS 17/2.8) stably transfected with estrogen receptor
30. Alterations of maternal estrogen levels during gestation affect the skeleton of female offspring
31. Transient exposure to estrogens during development modulates osteoclastogenesis in adulthood
32. Bone acid phosphatase; Tartate resistant acid phosphatase as a marker of osteoclast function
33. Expression of estrogen receptor-α in cells of the osteoclastic lineage
34. Estrogen regulation of gene expression in osteoblasts and osteoclasts
35. Humang giant cell tumors of the bone (osteoclastomas) are estrogen target cells
36. The melanoma cell line B16 induces osteoclastogenesis and stimulates c-Src expression in mouse bone marrow cultures
37. Expression and regulation of Runx/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts
38. Conditioned medium of estradiol-treated osteoblasts inhibits osteoclast maturation and function in vitro
39. Comparative effects of estrogen and anti-estrogens on differentiation of osteoblasts in mouse bone marrow culture
40. Involutional osteoporosis
41. Human bone cells in vitro
42. Raloxifene, tamoxifene, nafoxidine or estrogen effects on reproductive and non-reproductive tissue in ovariectomized rats
43. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-jun repression
44. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton
45. Osteoblast isolation; New developments and methods
46. Two domains unique to osteoblast-specific transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfβ
47. Mechanism of action of estrogen on cancellous bone balance in tibiae ovariectomized growing rats; Inhibition of indices of formation and resorption
48. Raloxifene preserves bone strength and bone mass in ovariectomized rats
49. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone deficient rats
50. Expression and localization of estrogen receptor beta in murine and human bone
51. Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats
52. Identification of an estrogen response element activated by metabolites of estradiol and raloxifene